The anti-cancer activities of jasmonates
Jasmonates, plant stress hormones protecting the plant from microbial pathogens and environmental stresses, were also discovered to have toxic activities toward mammalian cancer cells. Methyl jasmonate (MJ) was found to be the most active anti-cancer derivate among natural jasmonates, exhibiting a specific cell death-induction effect toward several cancer cells. Since that discovery of jasmonates-inducing cancer cell death, the molecular mechanism of action of jasmonates leading to cell death was deciphered. Moreover, in addition to the direct effects of MJ on cancer cell death, it was found to deregulate several genes and affect various intracellular factors and cellular processes, such as sensitization of apoptotic cell death induced by TRAIL, cancer cell migration attenuation, cell cycle arrest, and differentiation. This mini-review summarizes over a decade of research of jasmonates as anti-cancer agents.
KeywordsJasmonates Cancer Apoptosis Mitochondria Cancer metabolism Reactive oxygen species
This review is dedicated to the memorial and honor of the late Professor Eliezer Flescher, who was the pioneer scientist on the subject of jasmonates in cancer therapy. This work was supported in part by a grant from the Cooperation Program in Cancer Research of the Deutsches Krebsforschunszentrum (DKFZ) and by the Israel Cancer Association to E. Flescher.
Conflict of interest
- 4.Davies PJ (2004) Plant hormones-biosynthesis, signal transduction. Kluwer Academic Publishers, ActionGoogle Scholar
- 27.Ezekwudo D, Shashidharamurthy R, Devineni D, Bozeman E, Palaniappan R, Selvaraj P (2008) Inhibition of expression of anti-apoptotic protein Bcl-2 and induction of cell death in radioresistant human prostate adenocarcinoma cell line (PC-3) by methyl jasmonate. Cancer Lett 270(2):277–285CrossRefPubMedGoogle Scholar
- 58.Matsuura K, Shiraishi H, Hara A, Sato K, Deyashiki Y, Ninomiya M, Sakai S (1998) Identification of a principal mRNA species for human 3alpha-hydroxysteroid dehydrogenase isoform (AKR1C3) that exhibits high prostaglandin D2 11-ketoreductase activity. J Biochem 124(5):940–946CrossRefPubMedGoogle Scholar
- 59.Lan Q, Mumford JL, Shen M, Demarini DM, Bonner MR, He X, Yeager M, Welch R, Chanock S, Tian L, Chapman RS, Zheng T, Keohavong P, Caporaso N, Rothman N (2004) Oxidative damage-related genes AKR1C3 and OGG1 modulate risks for lung cancer due to exposure to PAH-rich coal combustion emissions. Carcinogenesis 25(11):2177–2181CrossRefPubMedGoogle Scholar
- 60.Frei E, BasJr RC, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Gansler TS (2003) Principles of Dose, Schedule, and Combination Chemotherapy. Cancer Medicine. Cancer Medicine, BC Decker, pp 817–837Google Scholar
- 61.Takimoto C, Coia LR, Hoskins WJ, Wagman LD (2005) Principles of Oncologic Pharmacotherapy. A Multidisciplinary Approach. CMP Healthcare Media, Manhasset, Cancer Management, pp 23–42Google Scholar
- 73.Milrot E, Jackman A, Flescher E, Gonen P, Kelson I, Keisari Y, Sherman L (2012) Enhanced killing of cervical cancer cells by combinations of methyl jasmonate with cisplatin, X or alpha radiation. Invest New DrugsGoogle Scholar
- 77.Tsumura H, Akimoto M, Kiyota H, Ishii Y, Ishikura H, Honma Y (2008) Gene expression profiles in differentiating leukemia cells induced by methyl jasmonate are similar to those of cytokinins and methyl jasmonate analogs induce the differentiation of human leukemia cells in primary culture. Leukemia 23(4):753–760CrossRefPubMedGoogle Scholar